FGFR1 and breast carcinoma: With the current number of available options for advanced HR+ breast cancer [31–38], the development of FGFR inhibitors will be challenging unless a biomarker that narrows down the population that will benefit from FGFR1 blockade and a specific therapeutic niche are determined.